Competition & Peer Data API & CSV Delivery

Quotient Limited's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Quotient Limited (QTNT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2022
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-11.03 %
Q4 2022
Net Margin
-147.23 %
Q4 2022

Key Findings: Quotient Limited vs Its Competitors

  • TTM: Trailing 12-month revenue of 36M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is holding steady (-0.2% annualized vs trailing 12 months).
  • Peer revenue share: Quotient Limited accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

QTNT Sales vs. its Competitors, Q4 2022

Quotient Limited generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/QTNT/competitors
https://api.csimarket.com/api/v1/companies/QTNT/relationships
https://api.csimarket.com/api/v1/companies/QTNT/similar
Programmatic access for models, analytics, and integration workflows.

For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 2.5% year over year, combined, vs -11.0% for Quotient Limited. Quotient Limited's share of combined industry revenue moved from 0.30% to 0.26%, a loss of 0.04 percentage points.

Quotient Limited's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Quotient Limited No No No Yes
High-Confidence Competitors (1) 0% 100% 100% 0%
Similar Growth & Profitability (8) 0.00 % (0 of 8) 37.50 % (3 of 8) 37.50 % (3 of 8) 42.90 % (3 of 7)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q4 2022

100%market share
  • Quotient Limited100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Quotient Limited and its 0 tracked competitors.

See Quotient Limited's full market share breakdown »

QTNT Stock Performance relative to its Competitors

QTNT Competitors (weighted) Percent change over the selected range

QTNT Stock Performance relative to High-Confidence Competitors

QTNT High-Confidence Competitors (equal-weighted, 1) Percent change over the selected range

QTNT Stock Performance relative to Similar Growth & Profitability Competitors

QTNT Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

Quotient Limited's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Societal Cdmo Inc Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Quotient Limited's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.